Integration of Routine Parameters of Glycemic Variability in a Simple Screening Method for Partial Remission in Children with Type 1 Diabetes
Open Access
- 1 January 2018
- journal article
- research article
- Published by Hindawi Limited in Journal of Diabetes Research
- Vol. 2018, 1-9
- https://doi.org/10.1155/2018/5936360
Abstract
Although different criteria were used to define partial remission in type 1 diabetes, the IDAA1C formula has prevailed as it correlates with stimulated C-peptide levels. Our retrospective study evaluated clinical variables associated with the occurrence of IDAA1C-defined partial remission in a series of 239 pediatric patients. Diabetic ketoacidosis and age at diagnosis, but no other clinical feature, influenced the occurrence of remission. We then evaluated whether parameters of glycemic variability used in clinical routine may reliably define partial remission, as these would alleviate confounding factors related to insulin treatment. Using multiple linear regression, we observed that HbA1C levels and percentage of normoglycemia were efficient and sufficient to predict partial remission. These parameters were entered into a formula, called glycemic target-adjusted HbA1C (GTAA(1C)),that corresponded to HbA(1C(%)) -(3 x% of normoglycemic values(70-180 mg/dL)). With a threshold of 4.5, this alternative formula predicted partial remission with a sensitivity and a specificity of 72.3% and 92%, respectively, and yielded strong correlation with IDAA(1C) levels and BETA-2 score, which is a correlate of beta-cell function after islet transplantation. We propose GTAA(1C), based on routine and objective markers of glycemic variability, as a valid alternative for definition of partial remission in type 1 diabetes.This publication has 58 references indexed in Scilit:
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registryPediatric Diabetes, 2013
- Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell FunctionDiabetes Care, 2012
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist StudyDiabetes, 2010
- New Definition for the Partial Remission Period in Children and Adolescents With Type 1 DiabetesDiabetes Care, 2009
- β-Cell Mass and Type 1 DiabetesDiabetes, 2008
- Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic PatientsDiabetes, 2008
- Age, metabolic control and type of insulin regime influences health-related quality of life in children and adolescents with type 1 diabetes mellitusEuropean Journal of Pediatrics, 2005
- Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial ? a large-scale multicentre studyEuropean Journal of Pediatrics, 2004